ChloeEAtreyaMD

Oncology • San Francisco, CA

Instructor, Medicine, UCSF School of Medicine

Join to view full profile

Dr. Atreya is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Atreya's full profile

Already have an account?

Office
1600 Divisadero St
Fl 4
San Francisco, CA 94143
Phone+1 415-353-9888

Fax+1 415-353-9931

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2008 - 2010
University of WashingtonResidency, Internal Medicine, 2005 - 2008
Yale School of MedicineClass of 2005

Certifications & Licensure

CA State Medical License 2008 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma Start of enrollment: 2012 Oct 05
Completed
Phase 2
Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2018 Apr 18
Completed
Phase 2
Web-based Mindfulness Meditation in Reducing Distress in Participants With Metastatic Gastrointestinal Cancer and Their Caregivers Start of enrollment: 2018 May 07
Completed
Not Applicable
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases Start of enrollment: 2019 Jul 22
Recruiting
Phase 2
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer Start of enrollment: 2020 Aug 31
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

382 citations
Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-Mutant colorectal cancer
Ryan B. Corcoran, Chloe E. Atreya, Gerald Steven Falchook, Eunice L. Kwak, David P. Ryan
Journal of Clinical Oncology. 2015-09-21
39 citations
PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival
Chloe E. Atreya, Zaina Sangale, Nafei Xu, Mary Matli, Eliso Tikishvili
Cancer Medicine. 2013-08-01
540 citations
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger
Journal of Clinical Oncology. 2020-01-01

Journal Articles

Association of Diet Quality with Survival Among People with Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial
Kimmie Ng, Chloe Atreya, Howard S Hochster, James N Atkins, Richard M Goldberg, Charles D Blanke, Jeffrey A Meyerhardt, JAMA Network Open

Lectures

Molecular characterization of a gastric cancer transmitted from an organ donor to four transplant recipients.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020

Press Mentions

OncLive® Hosts State of the Science Summit™: Gastrointestinal MalignanciesFebruary 22nd, 2018
New ‘Immunoprofiler’ Initiative Will Advance Drug Discovery, Precision Immunotherapy for CancerJanuary 19th, 2017
Triplet Therapy Effective in BRAF-Mutant mCRCJune 8th, 2015